Zoetis Inc. (ZTS) Shares Sold by State Street Corp
State Street Corp lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.9% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,638,259 shares of the company’s stock after selling 618,298 shares during the period. State Street Corp owned about 4.22% of Zoetis worth $1,287,412,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the company. Guardian Life Insurance Co. of America raised its holdings in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares in the last quarter. Sii Investments Inc. WI raised its holdings in shares of Zoetis by 0.3% during the 1st quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after buying an additional 23 shares in the last quarter. Ironwood Investment Management LLC raised its holdings in shares of Zoetis by 0.7% during the 2nd quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after buying an additional 48 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Zoetis by 1.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after buying an additional 55 shares in the last quarter. Finally, First Interstate Bank raised its holdings in shares of Zoetis by 3.5% during the 1st quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares in the last quarter. 93.20% of the stock is owned by institutional investors.
Shares of Zoetis Inc. (NYSE:ZTS) remained flat at $63.75 during trading on Friday. The stock had a trading volume of 2,543,606 shares. The company has a market capitalization of $31.18 billion, a PE ratio of 36.04 and a beta of 1.02. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $65.83. The stock’s 50-day moving average is $63.41 and its 200-day moving average is $60.49.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter last year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities research analysts expect that Zoetis Inc. will post $2.34 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.66%. Zoetis’s payout ratio is 23.73%.
A number of equities analysts have recently commented on the company. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $62.00 price target on shares of Zoetis in a report on Monday, August 7th. BidaskClub cut Zoetis from a “hold” rating to a “sell” rating in a report on Friday. Cowen and Company set a $70.00 price target on Zoetis and gave the stock a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Zoetis in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the stock a “buy” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $65.44.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.